Su1413 Sof/VEL for 12 Weeks Results in High SVR 12 Rates in Subjects With Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy Fron the ASTRAL-1, ASTRAL-2 and ASTRAL-3 Studies